MGEA5抗体;MGEA5 Antibody—艾普蒂

+ +

•  

   

     All lanes use the Antibody at 1:500 dilution for 1 hour at room temperature.    

  
  

•  

   

     Western blot analysis of MGEA5 expression in JAR cell lysate.    

  
  

•  

   

     Immunofluorescent analysis using the Antibody at 1:50 dilution.    

  
  

•  

   

     Immunofluorescent analysis using the Antibody at 1:50 dilution.    

  
  

The MGEA5 antibody targets the protein meningioma-expressed antigen 5 (MGEA5), also known as O-GlcNAcase (OGA), an enzyme involved in the removal of O-linked β-N-acetylglucosamine (O-GlcNAc) post-translational modifications from cellular proteins. Discovered in studies of meningiomas, MGEA5/OGA plays a critical role in regulating O-GlcNAcylation, a dynamic process that influences protein function, cellular signaling, and gene expression. Dysregulation of O-GlcNAc cycling has been linked to neurodegenerative diseases, diabetes, and cancer.

MGEA5 antibodies are widely used in research to investigate O-GlcNAc metabolism and its impact on cellular processes such as stress response, apoptosis, and epigenetic regulation. In neurodegenerative contexts, altered O-GlcNAcylation is associated with tau and amyloid-β pathologies in Alzheimer’s disease. MGEA5 inhibitors are also explored for therapeutic potential in metabolic disorders.

As a diagnostic tool, MGEA5 antibodies help detect protein expression patterns in tumors and other tissues, aiding in understanding disease mechanisms. Their application extends to studying crosstalk between O-GlcNAcylation and phosphorylation, a key area in cellular signaling research. Overall, MGEA5 antibodies serve as vital reagents for elucidating the biological and pathological roles of O-GlcNAc dynamics.